There are 2137 resources available
1405P - Survival of patients with non-small cell lung cancer and exon 20 insertion mutation from the Czech Republic
Presenter: Jana Skrickova
Session: E-Poster Display
Resources:
Abstract
1406P - External quality assessment of immunohistochemistry, in-situ hybridization and RNA/DNA sequencing for ROS1 testing reveals high concordance for all methods
Presenter: Markus Ball
Session: E-Poster Display
Resources:
Abstract
1407P - Lymphocyte subsets predict clinical outcomes of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
Presenter: Yiqian Liu
Session: E-Poster Display
Resources:
Abstract
1408P - The landscape of ROS1 fusion in patients with non-small cell lung cancer in China
Presenter: Min Chen
Session: E-Poster Display
Resources:
Abstract
1409P - Comparing different methods of FGFR1 aberrations analysis in squamous cell lung cancer (SqCLC) targeted therapy
Presenter: Monika Skupinska
Session: E-Poster Display
Resources:
Abstract
1410P - Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC
Presenter: Jiaxin Niu
Session: E-Poster Display
Resources:
Abstract
1411TiP - GFPC 06-2018: A multicenter non-randomized phase II study evaluating platinum-pemetrexed-atezolizumab (+/-bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after targeted therapies
Presenter: Olivier Bylicki
Session: E-Poster Display
Resources:
Abstract
1412TiP - Mobocertinib (TAK-788) as first-line treatment vs platinum-based chemotherapy (CT) for NSCLC with EGFR exon 20 insertions (exon20ins)
Presenter: Pasi Jänne
Session: E-Poster Display
Resources:
Abstract
1413TiP - LIBRETTO-431: Selpercatinib in treatment (Tx)-naïve patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC)
Presenter: Herbert Loong
Session: E-Poster Display
Resources:
Abstract
1414TiP - Evaluating telisotuzumab vedotin in combination with osimertinib in patients with advanced non-small cell lung cancer: A phase I/Ib study cohort
Presenter: D. Ross Camidge
Session: E-Poster Display
Resources:
Abstract